Home Cart Sign in  
Chemical Structure| 300851-67-6 Chemical Structure| 300851-67-6

Structure of 4-CMTB
CAS No.: 300851-67-6

Chemical Structure| 300851-67-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC50=6.38).

Synonyms: (±)-4-CMTB

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 4-CMTB

CAS No. :300851-67-6
Formula : C14H15ClN2OS
M.W : 294.80
SMILES Code : CC(C)C(C1=CC=C(Cl)C=C1)C(NC2=NC=CS2)=O
Synonyms :
(±)-4-CMTB
MDL No. :MFCD02666163
InChI Key :AZYDQCGCBQYFSE-UHFFFAOYSA-N
Pubchem ID :4307629

Safety of 4-CMTB

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Related Pathways of 4-CMTB

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MH-S cells 5 µM, 10 µM 48 h 4-CMTB decreased the protein expressions of Arg1 and p-Stat6, and mRNA levels of M2-associated genes, including Arg1, MRC1, FIZZ1, and YM1. Clin Exp Immunol. 2022 Jan 28;207(1):53-64
RBL-2H3 cells 1 µM 30 min To evaluate the inhibitory effect of 4-CMTB on degranulation in RBL-2H3 cells. Results showed that 4-CMTB inhibited the release of β-hexosaminidase in a concentration-dependent manner and significantly suppressed histamine release at 1 µM. Biomol Ther (Seoul). 2021 Jul 1;29(4):427-433
SW-480 10-200 µM 48 h To evaluate the effect of 4-CMTB on cancer cell growth, results showed that 4-CMTB significantly reduced the growth of SW-480 cells Pharmacol Rep. 2024 Dec;76(6):1403-1414
CCD 841 CoN 10-200 µM 48 h To evaluate the effect of 4-CMTB on non-cancer cell growth, results showed that 4-CMTB significantly reduced the growth of CCD 841 CoN cells Pharmacol Rep. 2024 Dec;76(6):1403-1414
Caco-2 human colonic epithelial cells 30 μM 24 h To evaluate the cytotoxicity of 4-CMTB and its effect on IL-6 secretion in Caco-2 cells. Results showed that 4-CMTB at 30 μM did not significantly affect cell viability, but its effect on IL-6 secretion was not clearly stated. Nutrients. 2021 Aug 6;13(8):2716
RAW264.7 macrophages 30 μM 48 h To evaluate the cytotoxicity of 4-CMTB and its effect on NO secretion in RAW264.7 macrophages. Results showed that 4-CMTB at 30 μM did not significantly affect cell viability, but its effect on NO secretion was not clearly stated. Nutrients. 2021 Aug 6;13(8):2716
HEK293S cells 10 μM Used for structural studies, co-activating the FFA2-Gi signaling complex with TUG-1375 Nat Commun. 2025 Mar 26;16(1):2809

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Ovalbumin-induced allergic asthma model Intraperitoneal injection 10 mg/kg or 20 mg/kg Administered 30 minutes before each OVA challenge, for 3 days To evaluate the therapeutic effect of 4-CMTB on ovalbumin-induced allergic asthma. Results showed that 4-CMTB significantly reduced immune cell numbers in bronchoalveolar lavage fluid, suppressed the expression of inflammatory Th2 cytokines (IL-4, IL-5, and IL-13) in lung tissues, and reduced mucin production and inflammation in the lungs. Biomol Ther (Seoul). 2021 Jul 1;29(4):427-433
Balb/c mice DNCB-induced atopic dermatitis model Intraperitoneal injection 10 mg/kg From day 19 until completion of the study, administered 30 min prior to each DNCB challenge To evaluate the therapeutic effect of 4-CMTB on DNCB-induced atopic dermatitis. Results showed that 4-CMTB significantly suppressed DNCB-induced increases in IgE levels, ear skin hypertrophy, and mast cell accumulation, reduced DNCB-induced increases in Th2 cytokine (IL-4 and IL-13) levels in the ears, and blocked DNCB-induced lymph node enlargement. Biomol Ther (Seoul). 2020 May 1;28(3):267-271
Balb/C mice AOM/DSS-induced colitis-associated colorectal cancer model Intraperitoneal injection 10 mg/kg Every 3 days for 14 weeks To evaluate the effect of 4-CMTB on AOM/DSS-induced CACRC model, results showed that 4-CMTB did not significantly affect the number of tumors or other cancer parameters Pharmacol Rep. 2024 Dec;76(6):1403-1414
C57BL/6 mice TNBS-induced colitis model and DSS-induced colitis model Intraperitoneal injection 1 mg/kg body weight Twice daily for 4 days To evaluate the therapeutic effect of 4-CMTB in TNBS- and DSS-induced colitis models. Results showed that 4-CMTB did not significantly improve macroscopic parameters and MPO activity in the TNBS model, but its effect in the DSS model was not clearly stated. Nutrients. 2021 Aug 6;13(8):2716

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.39mL

0.68mL

0.34mL

16.96mL

3.39mL

1.70mL

33.92mL

6.78mL

3.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories